<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-151380</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?</dc:title>
<dc:description xml:lang="en">No disponible</dc:description>
<dc:creator>Alcántara Montero, A</dc:creator>
<dc:creator>Brenes Bermúdez, FJ</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Actas Urol Esp;40(4): 268-269, mayo 2016.</dc:source>
<dc:identifier>ibc-151380</dc:identifier>
<dc:title xml:lang="es">¿Finasterida o dutasterida para el tratamiento farmacológico de los síntomas del tracto urinario inferior en el varón debidos a hiperplasia benigna de próstata?</dc:title>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d31467^s22073</dc:subject>
<dc:subject>^d29638</dc:subject>
<dc:subject>^d31467^s22000</dc:subject>
<dc:subject>^d14970^s22054</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30706</dc:subject>
<dc:subject>^d14970^s22012</dc:subject>
<dc:subject>^d14970^s22067</dc:subject>
<dc:subject>^d28571</dc:subject>
<dc:subject>^d24852</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d31467^s22079</dc:subject>
<dc:subject>^d55943^s22079</dc:subject>
<dc:subject>^d55943^s22000</dc:subject>
<dc:subject>^d11913^s22067</dc:subject>
<dc:subject>^d11913^s22054</dc:subject>
<dc:subject>^d11913^s22016</dc:subject>
<dc:subject>^d31495</dc:subject>
<dc:subject>^d30152</dc:subject>
<dc:subject>^d55943^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201605</dc:date>
</metadata>
</record>
</ibecs-document>
